Literature DB >> 29242516

MRONJ risk of adjuvant bisphosphonates in early stage breast cancer.

V Patel1, J Mansi1, S Ghosh1, J Kwok1, M Burke1, D Reilly1, N Nizarali1, C Sproat1, K Chia1.   

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) has most commonly been associated with bisphosphonates. The routine uses of these drugs are now well established predominantly in metastatic cancer with bone involvement, multiple myeloma, hypercalcaemia, osteoporosis and Paget's disease. Recently, however, the use of bisphosphonates in early breast cancer has shown a reduction in breast cancer recurrence and breast cancer deaths. This new indication for their use approximates to a further 20,000 women per year in the UK being prescribed bisphosphonates. In this article, we consider the dental impact of this new use of bisphosphonates, report on the rates of MRONJ seen in early breast cancer bisphosphonate trials and discuss strategies aimed at minimising the risk of bisphosphonate-exposed patients developing MRONJ.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29242516     DOI： 10.1038/sj.bdj.2017.1039

Source DB:  PubMed          Journal:  Br Dent J        ISSN： 0007-0610            Impact factor:   1.626


  22 in total

Review 1.  Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.

Authors:  P Hadji; R E Coleman; C Wilson; T J Powles; P Clézardin; M Aapro; L Costa; J-J Body; C Markopoulos; D Santini; I Diel; A Di Leo; D Cameron; D Dodwell; I Smith; M Gnant; R Gray; N Harbeck; B Thurlimann; M Untch; J Cortes; M Martin; U-S Albert; P-F Conte; B Ejlertsen; J Bergh; M Kaufmann; I Holen
Journal:  Ann Oncol       Date:  2015-12-17       Impact factor: 32.976

2.  American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.

Authors:  Catherine H Van Poznak; Sarah Temin; Gary C Yee; Nora A Janjan; William E Barlow; J Sybil Biermann; Linda D Bosserman; Cindy Geoghegan; Bruce E Hillner; Richard L Theriault; Dan S Zuckerman; Jamie H Von Roenn
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 44.544

3.  The financial burden for the surgical management of osteoradionecrosis.

Authors:  V Patel; L Ormondroyd; A Lyons; M McGurk
Journal:  Br Dent J       Date:  2017-02-10       Impact factor: 1.626

4.  Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.

Authors:  Lee S Rosen; David Gordon; Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh; M Krzakowski; M Pawlicki; Paul de Souza; Ming Zheng; Gladys Urbanowitz; Dirk Reitsma; John J Seaman
Journal:  J Clin Oncol       Date:  2003-08-15       Impact factor: 44.544

5.  Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.

Authors:  R Coleman; R de Boer; H Eidtmann; A Llombart; N Davidson; P Neven; G von Minckwitz; H P Sleeboom; J Forbes; C Barrios; A Frassoldati; I Campbell; O Paija; N Martin; A Modi; N Bundred
Journal:  Ann Oncol       Date:  2012-10-09       Impact factor: 32.976

6.  Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.

Authors:  M A Dimopoulos; E Kastritis; C Bamia; I Melakopoulos; D Gika; M Roussou; M Migkou; E Eleftherakis-Papaiakovou; D Christoulas; E Terpos; A Bamias
Journal:  Ann Oncol       Date:  2008-08-09       Impact factor: 32.976

7.  German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.

Authors:  Gunter von Minckwitz; Volker Möbus; Andreas Schneeweiss; Jens Huober; Christoph Thomssen; Michael Untch; Christian Jackisch; Ingo J Diel; Dirk Elling; Bettina Conrad; Rolf Kreienberg; Volkmar Müller; Hans-Joachim Lück; Ingo Bauerfeind; Michael Clemens; Marcus Schmidt; Stefanie Noeding; Helmut Forstbauer; Jana Barinoff; Antje Belau; Valentina Nekljudova; Nadia Harbeck; Sibylle Loibl
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

8.  Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.

Authors:  C I Ripamonti; M Maniezzo; T Campa; E Fagnoni; C Brunelli; G Saibene; C Bareggi; L Ascani; E Cislaghi
Journal:  Ann Oncol       Date:  2008-07-22       Impact factor: 32.976

Review 9.  Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.

Authors:  Aliya A Khan; Archie Morrison; David A Hanley; Dieter Felsenberg; Laurie K McCauley; Felice O'Ryan; Ian R Reid; Salvatore L Ruggiero; Akira Taguchi; Sotirios Tetradis; Nelson B Watts; Maria Luisa Brandi; Edmund Peters; Teresa Guise; Richard Eastell; Angela M Cheung; Suzanne N Morin; Basel Masri; Cyrus Cooper; Sarah L Morgan; Barbara Obermayer-Pietsch; Bente L Langdahl; Rana Al Dabagh; K Shawn Davison; David L Kendler; George K Sándor; Robert G Josse; Mohit Bhandari; Mohamed El Rabbany; Dominique D Pierroz; Riad Sulimani; Deborah P Saunders; Jacques P Brown; Juliet Compston
Journal:  J Bone Miner Res       Date:  2015-01       Impact factor: 6.741

10.  American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; John Fantasia; Reginald Goodday; Tara Aghaloo; Bhoomi Mehrotra; Felice O'Ryan
Journal:  J Oral Maxillofac Surg       Date:  2014-05-05       Impact factor: 2.136
View more
  4 in total

1.  Photodynamic Therapy as an adjunct in the Treatment of Medication-Related Osteonecrosis of the Jaw: A Case Report.

Authors:  Marcelo Vieira da Costa Almeida; Antonio C Moura; Lúcia Santos; Luciana Gominho; Ully Dias Nascimento Távora Cavalcanti; Kaline Romeiro
Journal:  J Lasers Med Sci       Date:  2021-03-08

2.  No studies.

Authors:  K Altundag
Journal:  Br Dent J       Date:  2018-02-23       Impact factor: 1.626

3.  General dental practitioners' perceptions of, and attitudes towards, improving patient safety through a multidisciplinary approach to the prevention of medication-related osteonecrosis of the jaw (MRONJ): a qualitative study in the North East of England.

Authors:  Andrew Sturrock; Philip M Preshaw; Catherine Hayes; Scott Wilkes
Journal:  BMJ Open       Date:  2019-06-17       Impact factor: 2.692

Review 4.  Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals.

Authors:  Lawrence Drudge-Coates; Tim Van den Wyngaert; Morten Schiødt; H A M van Muilekom; Gaston Demonty; Sven Otto
Journal:  Support Care Cancer       Date:  2020-04-19       Impact factor: 3.603
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.